The Psychedelic Revolution: A New Era of Mental Health Treatment

The world of mental health treatment is on the brink of a major shift. A new class of drugs, known as psychedelics, is promising to revolutionize the way we approach mental health disorders. This article will delve into the science behind these drugs, the companies leading the charge in this new frontier, and the potential financial implications of this burgeoning industry.


Xander Gray

7/14/20234 min read

The Science Behind Psychedelic Medications

Psychedelic medications work by interacting with various neurotransmitters in the brain. Classic psychedelics, such as LSD and psilocybin, bind to the serotonin 2A receptor, one of the 15 specialized receptor molecules the serotonin system uses to coordinate brain activity. This interaction is believed to be responsible for the hallucinogenic effects of these substances.

Other compounds, such as MDMA, are classified as entactogens. These substances alter social perceptions and amplify empathy, leading to feelings of increased connection with others. They do not directly act on the serotonin 2A receptor, which is why their effects are different from classic hallucinogens.

Psychedelics also affect other neurotransmitters such as dopamine, norepinephrine, and glutamate. The specific interactions and effects can vary depending on the substance, but they all lead to changes in perception, mood, and cognitive processes.

Company Overviews

Four companies, Mind Medicine (MindMed) Inc., Cybin Inc., Compass Pathways, and ATAI Life Sciences, are leading the charge in the development of psychedelic medications.

MindMed, a neuro-pharmaceutical company, is pioneering the development of psychedelic-inspired medicines. The company's diverse development pipeline includes projects involving LSD, MDMA, DMT, and an Ibogaine derivative (18-MC), all aimed at treating a range of mental health issues, from addiction to anxiety.

Cybin Inc., on the other hand, is a leading biotechnology company focused on progressing psychedelic therapeutics. The company is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels.

Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company's focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

ATAI Life Sciences is a global biotechnology company builder that envisions an end to mental illnesses. The company's mission is to acquire, incubate, and efficiently develop innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

Financial Overview

As of July 2023, MindMed has a market cap of $1.01B with a volume of 1.39M. The company's 52-week high is $6.98, and its 52-week low is $1.01. The company's EPS (TTM) is -0.23. The Price to Earnings (P/E) ratio is 74, indicating the price investors are willing to pay per dollar of earnings. The company's Price to Book Value (P/B) ratio is 7, suggesting that the market perceives the company's book value (assets - liabilities) to be undervalued.

Cybin Inc.'s closing price as of July 13, 2023, was $0.47 USD with a volume of 2,386,094. The 52-week range for the stock price is $0.21 - $1.14. The company's EBITDA stands at $13.63 million. Cybin Inc.'s total assets amount to $48.23 million, with cash and short-term investments making up $16.63 million of this total. The company has total liabilities of $5.66 million. The book value per share for Cybin Inc. is $0.24.

Compass Pathways has a market cap of $337.00M. The company's revenue for the last fiscal year was $0.00M, and it reported a net income of -$95.00M. The company's total assets are $179.00M, and its total liabilities are $28.00M.

ATAI Life Sciences has a market cap of $1.00B. The company's revenue for the last fiscal year was $0.00M, and it reported a net income of -$204.00M. The company's total assets are $214.00M, and its total liabilities are $45.00M.

Future Valuations

Given the promising developments in the field of psychedelic medicine, all four companies have the potential for significant growth in the coming years. The increasing acceptance and recognition of the therapeutic benefits of psychedelics could lead to a surge in demand for these treatments, driving up the valuations of companies that are at the forefront of this revolution.

However, it's important to note that these are still early days in the field of psychedelic medicine. While the potential is enormous, there are also significant risks involved. All companies will need to navigate regulatory hurdles, clinical trials, and the challenges of bringing new treatments to market.

Technical Analysis

The technical analysis of the stock prices of these companies shows that they are all in the early stages of a potential uptrend. This is based on the analysis of their daily charts. MindMed (MNMD) has confirmed its uptrend, with its stock price showing a consistent upward movement. The stock price of Cybin (CYBN), on the other hand, is showing signs of a potential uptrend, but this has not yet been confirmed. Compass Pathways (CMPS) and ATAI Life Sciences (ATAI) are also showing signs of a potential uptrend. However, these trends have not yet been confirmed and investors should keep a close eye on these stocks.



This article is for informational purposes only and should not be considered financial advice. The author does not hold any position in MindMed, Cybin Inc., Compass Pathways, or ATAI Life Sciences. Always do your own research and consider your financial position before making investment decisions.

Subscribe to our newsletter